JP Morgan Chase’s Ionis Pharmaceuticals IONS Stock Holding History

JP Morgan Chase’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12M	Buy	+165,000	New	+$13M	﹤0.01%	2515
2025 Q2	–	Sell	-30,000	Closed	-$905K	–	7370
2025 Q1	$905K	Hold	30,000	–	–	﹤0.01%	4420
2024 Q4	$1.05M	Buy	+30,000	New	+$1.12M	﹤0.01%	4602
2024 Q3	–	Sell	-138,700	Closed	-$6.61M	–	7544
2024 Q2	$6.61M	Buy	138,700 +43,800	+46%	+$1.8M	﹤0.01%	2818
2024 Q1	$4.11M	Buy	94,900 +64,900	+216%	+$3.09M	﹤0.01%	3263
2023 Q4	$1.52M	Hold	30,000	–	–	﹤0.01%	4041
2023 Q3	$1.36M	Buy	+30,000	New	+$1.24M	﹤0.01%	3854
2022 Q2	–	Sell	-47,300	Closed	-$1.75M	–	6668
2022 Q1	$1.75M	Hold	47,300	–	–	﹤0.01%	3856
2021 Q4	$1.44M	Hold	47,300	–	–	﹤0.01%	4110
2021 Q3	$1.59M	Buy	+47,300	New	+$1.78M	﹤0.01%	3966
2019 Q3	–	Sell	-50,000	Closed	-$3.23M	–	5843
2019 Q2	$3.23M	Buy	50,000 +14,000	+39%	+$990K	﹤0.01%	3013
2019 Q1	$2.92M	Buy	+36,000	New	+$2.32M	﹤0.01%	3064
2017 Q3	–	Sell	-20,000	Closed	-$1.02M	–	5056
2017 Q2	$1.02M	Buy	+20,000	New	+$931K	﹤0.01%	3418

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase's IONS Position: Q1 2026 in Review

JP Morgan Chase increased its Ionis Pharmaceuticals (IONS) stake by 2.6% in Q1 2026, buying an estimated $4.64M and bringing the position to 2,363,567 shares worth $171M. The position accounts for 0.01% of the portfolio, ranked #760.

JP Morgan Chase first reported a position in IONS in Q2 2013 and has held it in 52 quarters since. The position peaked at $182M in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

JP Morgan Chase held 2,363,567 shares of Ionis Pharmaceuticals worth $171M as of Q1 2026.
JP Morgan Chase bought 58,775 Ionis Pharmaceuticals shares in Q1 2026, an estimated $4.64M.
Ionis Pharmaceuticals made up 0.01% of JP Morgan Chase's portfolio in Q1 2026, its #760 holding.
JP Morgan Chase first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
JP Morgan Chase's Ionis Pharmaceuticals position peaked at $182M in Q4 2025.
493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.